These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 22302874)

  • 1. The safety of yellow fever vaccine 17D or 17DD in children, pregnant women, HIV+ individuals, and older persons: systematic review.
    Thomas RE; Lorenzetti DL; Spragins W; Jackson D; Williamson T
    Am J Trop Med Hyg; 2012 Feb; 86(2):359-72. PubMed ID: 22302874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Active and passive surveillance of yellow fever vaccine 17D or 17DD-associated serious adverse events: systematic review.
    Thomas RE; Lorenzetti DL; Spragins W; Jackson D; Williamson T
    Vaccine; 2011 Jun; 29(28):4544-55. PubMed ID: 21549787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reporting rates of yellow fever vaccine 17D or 17DD-associated serious adverse events in pharmacovigilance data bases: systematic review.
    Thomas RE; Lorenzetti DL; Spragins W; Jackson D; Williamson T
    Curr Drug Saf; 2011 Jul; 6(3):145-54. PubMed ID: 22122389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How many published cases of serious adverse events after yellow fever vaccination meet Brighton Collaboration diagnostic criteria?
    Thomas RE; Spragins W; Lorenzetti DL
    Vaccine; 2013 Dec; 31(52):6201-9. PubMed ID: 24436960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced safety surveillance of STAMARIL® yellow fever vaccine provided under the expanded access investigational new drug program in the USA.
    Rojas A; Hachey W; Kaur G; Korejwo J; Muhammad R
    J Travel Med; 2023 Nov; 30(7):. PubMed ID: 37000007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Yellow fever vaccine for patients with HIV infection.
    Barte H; Horvath TH; Rutherford GW
    Cochrane Database Syst Rev; 2014 Jan; 2014(1):CD010929. PubMed ID: 24453061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse event reports following yellow fever vaccination.
    Lindsey NP; Schroeder BA; Miller ER; Braun MM; Hinckley AF; Marano N; Slade BA; Barnett ED; Brunette GW; Horan K; Staples JE; Kozarsky PE; Hayes EB
    Vaccine; 2008 Nov; 26(48):6077-82. PubMed ID: 18809449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of 17D derived yellow fever vaccines.
    Domingo C; Niedrig M
    Expert Opin Drug Saf; 2009 Mar; 8(2):211-21. PubMed ID: 19309249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse event reports following yellow fever vaccination, 2007-13.
    Lindsey NP; Rabe IB; Miller ER; Fischer M; Staples JE
    J Travel Med; 2016 May; 23(5):. PubMed ID: 27378369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Yellow fever vaccine usage in the United States and risk of neurotropic and viscerotropic disease: A retrospective cohort study using three healthcare databases.
    Ledlie S; Ricci C; Pan C; Rojas A; Khromava A; Li L
    Vaccine; 2022 Jan; 40(5):742-751. PubMed ID: 34996642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in HIV-infected people in Kenya (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial.
    Kimathi D; Juan-Giner A; Orindi B; Grantz KH; Bob NS; Cheruiyot S; Hamaluba M; Kamau N; Fall G; Dia M; Mosobo M; Moki F; Kiogora K; Chirro O; Thiong'o A; Mwendwa J; Guantai A; Karanja HK; Gitonga J; Mugo D; Ramko K; Faye O; Sanders EJ; Grais RF; Bejon P; Warimwe GM
    Lancet Infect Dis; 2023 Aug; 23(8):974-982. PubMed ID: 37127045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of yellow fever vaccine-associated viscerotropic disease among the elderly: a systematic review.
    Rafferty E; Duclos P; Yactayo S; Schuster M
    Vaccine; 2013 Dec; 31(49):5798-805. PubMed ID: 24079979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Yellow fever vaccine-associated viscerotropic disease: current perspectives.
    Thomas RE
    Drug Des Devel Ther; 2016; 10():3345-3353. PubMed ID: 27784992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Viscerotropic disease following yellow fever vaccination in Peru.
    Whittembury A; Ramirez G; Hernández H; Ropero AM; Waterman S; Ticona M; Brinton M; Uchuya J; Gershman M; Toledo W; Staples E; Campos C; Martínez M; Chang GJ; Cabezas C; Lanciotti R; Zaki S; Montgomery JM; Monath T; Hayes E
    Vaccine; 2009 Oct; 27(43):5974-81. PubMed ID: 19679215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of live vaccinations on immunosuppressive therapy in patients with immune-mediated inflammatory diseases, solid organ transplantation or after bone-marrow transplantation - A systematic review of randomized trials, observational studies and case reports.
    Croce E; Hatz C; Jonker EF; Visser LG; Jaeger VK; Bühler S
    Vaccine; 2017 Mar; 35(9):1216-1226. PubMed ID: 28162821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of fatal adverse events associated with 17DD yellow fever vaccine.
    Struchiner CJ; Luz PM; Dourado I; Sato HK; Aguiar SG; Ribeiro JG; Soares RC; Codeço CT
    Epidemiol Infect; 2004 Oct; 132(5):939-46. PubMed ID: 15473158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Yellow fever vaccine-associated viscerotropic disease and death in Spain.
    Doblas A; Domingo C; Bae HG; Bohórquez CL; de Ory F; Niedrig M; Mora D; Carrasco FJ; Tenorio A
    J Clin Virol; 2006 Jun; 36(2):156-8. PubMed ID: 16597510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Case Report: Fatal Viscerotropic Disease in a Young Woman Following Yellow Fever Vaccination.
    Brunaldi MO; Silva RJC; Fabro AT; de Almeida E Araujo DC; Basile-Filho A; Auxiliadora-Martins M; Menegueti MG; Beloddi MI; Alves Esposito DL; Lopes da Fonseca BA
    Am J Trop Med Hyg; 2021 Sep; 105(6):1803-1805. PubMed ID: 34491221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review of the risks and benefits of yellow fever vaccination including some new analyses.
    Monath TP
    Expert Rev Vaccines; 2012 Apr; 11(4):427-48. PubMed ID: 22551029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.